Revolution Medicines (RVMD) Q3 2024 earnings summary

Executive summary

• Advanced three RAS(ON) inhibitors (RMC-6236, RMC-6291, RMC-9805) with a focus on pivotal trials in pancreatic and non-small cell lung cancer, supported by strong clinical data and ongoing combination studies.

• Initiated first global phase III study (RASolute 302) for RMC-6236 in second-line metastatic PDAC; patients are actively being dosed.

• Presented compelling clinical data for RMC-6236 and initial data for RMC-9805 at major oncology meetings, showing promising efficacy and safety.

• Completed the acquisition of EQRx in November 2023, adding $1.1 billion in net cash and marketable securities, and issued 54.8 million shares as part of the transaction.

• Pipeline expansion includes new combinations and upcoming data disclosures in NSCLC and other tumor types.

Financial highlights

• Ended Q3 2024 with $1.55 billion in cash, cash equivalents, and marketable securities, projected to fund operations into 2027.

• Q3 2024 R&D expenses were $151.8 million, up from $107.7 million in Q3 2023, driven by clinical trial and personnel costs.

• Q3 2024 G&A expenses were $24.0 million, up from $15.5 million in Q3 2023, mainly due to headcount and commercial prep.

• Net loss for Q3 2024 was $156.3 million, compared to $108.4 million in Q3 2023; full-year 2024 net loss guidance reiterated at $560–600 million.

• No collaboration revenue recognized in Q3 2024 following the termination of the Sanofi agreement.

Outlook and guidance

• Cash runway supports planned operations, including two phase III second-line trials, into 2027.

• Expenses expected to increase in 2025 with the start of additional pivotal trials and commercial build-out.

• Phase III NSCLC trial initiation expected in Q1 2025, pending regulatory alignment.

• Full-year 2024 GAAP net loss projected between $560 million and $600 million, including $70–80 million in non-cash stock-based compensation.

• First-line PDAC phase III trial will proceed as soon as regimen and design are finalized, not waiting for second-line results.